Replies to post #61826 on Biotech Values

[DewDiligence]

>MNTA – Why didn't [the FDA] use Amphastar's technology? or Teva's? :-) <

As noted in the thread on SI, there’s a serious side to this: an increased likelihood that MNTA/Sandoz will possess the sole generic Lovenox on the US market. As you know, this a precondition for the outsized earnings numbers MNTA could garner from generic Lovenox.